Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIN457 (Secukinumab) IV Loading Dose in Psoriasis
NCT00805480Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2008
- Primary completion
- Sep 2010
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of secukinumab in plaque psoriasis (4 arms), sponsored by Novartis. Primary endpoints: Change From Baseline in Psoriasis Area and Severity Index (PASI) Scores at 12 weeks and Percentage of Participants Who Had Not Relapsed at Any Time in the Trial at 56 weeks. Started Dec 2008; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00805480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00805480.